| 1 | 
                
                    Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63.
                    
                        
                    
                 | 
            
                        
                | 2 | 
                
                    Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
                    
                        
                    
                 | 
            
                        
                | 3 | 
                
                    Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
                    
                        
                    
                 | 
            
                        
                | 4 | 
                
                    In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
                    
                        
                    
                 | 
            
                        
                | 5 | 
                
                    Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
                    
                        
                    
                 | 
            
                        
                | 6 | 
                
                    Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
                    
                        
                    
                 | 
            
                        
                | 7 | 
                
                    The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
                    
                        
                    
                 | 
            
                        
                | 8 | 
                
                    Company report (MediciNova)
                    
                        
                    
                 | 
            
                        
                | 9 | 
                
                    Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
                    
                        
                    
                 | 
            
            
            
                 | 
                 | 
                 | 
                 | 
                 | 
                 |